Transgenomic to Reduce Headcount as Q3 Revenues Drop 12 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic announced on Monday afternoon a consolidation of its R&D activities and a reduction in headcount as net sales for the third quarter fell 12 percent.

For the three months ended Sept. 30, the Omaha, Neb.-based company said sales shrank to $4.4 million, compared to $5.0 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.